cyrilzakka/clinical-trials huggingface dataset:
Nitric Oxide-mediated Cardioprotection During Cardiac Surgery With Cardiopulmonary Bypass

This prospective randomized study elucidates the effects of exogenous nitric oxide delivered to the extracorporeal circulation circuit for cardioprotection against ischemia-reperfusion injury during coronary artery bypass graft surgery with cardiopulmonary bypass.

The aim of this study is to investigate the effects of exogenous nitric oxide (NO) delivered to the extracorporeal circulation circuit for cardioprotection against ischemia-reperfusion injury during coronary artery bypass graft surgery (CABG) with cardiopulmonary bypass (CPB). A total of 60 patients with ischemic heart disease referred for CABG with CPB are included in prospective randomized study. Patients are randomized to receive standard treatment or surgery based on modified CPB protocol. According to modified protocol, 40-ppm NO is supplied to the CPB circuit during CABG. The primary endpoints are changes in cardiac troponin I (cTnI) levels at 6, 24, and 48 hours after surgery compared with baseline. The secondary end points are the changes in the levels of creatine kinase-muscle/brain (CK-MB) compared with baseline and vasoactive inotropic score (VIS) at 6, 24, and 48 hours. NO supplied to the CPB circuit exertes cardioprotective effect. Changes in cTnI, CK-MB, and VIS are considered indictors of the presence or absence of cardioprotective action of NO supplied to the CPB circuit.

Eligibility Criteria:
Inclusion Criteria:

* Coronary artery disease requiring coronary artery bypass grafting with the cardiopulmonary bypass.

Exclusion Criteria:

* Non-elective surgery, age over 70 years, left ventricular ejection fraction less than 35%, history of myocardial infarction within three months prior to surgery, chronic atrial fibrillation, diabetes mellitus, and the elevated levels of cardiac specific markers within 12 h prior to the intervention.
Multifocal HD-tDCS and Motor Function

The purpose of this study is to understand how the brain controls movement and how Non-invasive Brain Stimulation (NIBS) with a technique called High-density transcranial direct current stimulation (HD-tDCS) can alter brain processes to improve behavior. Participants in this study will be randomized to either HD-tDCS with standard intervention or personalized dose-controlled multifocal network-targeted HD-tDCS.

The hypothesis is that dexterous hand function will improve after a standard HD-tDCS dose and increase even more after personalized dose-controlled multifocal network-targeted HD-tDCS.

This project is the first of two projects. The second project will be registered as a separate project in the future and enroll participants from this project.

Eligibility Criteria:
Inclusion Criteria:

* Participants should be in good health with normal or corrected-to-normal visual acuity
* Right handed
* No history of neurological disorder
* English speaker
* Able to provide written consent prior to admission

Exclusion Criteria:

* Left-handed
* Participants are pregnant, suspect pregnancy or are attempting to become pregnant
* Have a pacemaker, intracardiac lines or any other medically implanted device or medicine pump
* Have cochlear hearing implants
* Taking drugs known to influence neural receptors that facilitate neuroplasticity (see protocol)
* Have non removable body piercings or have foreign objects in body
* Have metal anywhere in the head that could increase risk of serious injury (not including braces, dental fillings, etc.) (see protocol)
* Have a personal or family history of seizure/epilepsy
* Taking prescription drugs that lower the threshold for seizures
* Recent history of excessive alcohol consumption
* History of alcohol addiction/dependence
* Recent history of recreational drug use
* History of drug addiction/dependence
* Recent history of recreational drug use
* History of drug addiction/dependence
* Diagnosed with a stroke, brain hemorrhage, brain tumor, encephalitis.
* Diagnosed with multiple sclerosis
* Diagnosed with Parkinson's disease or Alzheimer's disease
* Diagnosed with depression in the past 6 months
* Diagnosed with attention deficit disorder, schizophrenia, manic depressive (bipolar) disorder
* Diagnosed with normal pressure hydrocephalus or increased intra-cranial pressure
* Diabetes requiring insulin treatment
* Any serious heart disorder or liver disease
Drug-Eluting Balloon or Drug-Eluting Stent in Acute Myocardial Infarction: A Randomized Controlled Trial

The objective of the study is to compare drug-coated balloon (DCB) with the gold standard drug-eluting stent (DES) in percutaneous coronary intervention (PCI) for patients presenting with ST-elevation myocardial infarction (STEMI).

Randomization will be performed after successful culprit-lesion preparation and confirmation that all angiographic entry criteria are met. Patients will be randomly assigned in a 1:1 fashion to receive either treatment with a Paclitaxel-coated balloon alone or second or third-generation DES.


Eligibility Criteria:
Inclusion Criteria:

* Age \>18 years with a life expectancy of \>1 year;
* Patients fulfilling criteria for STEMI (\>20 min of chest-pain; At least 1 mm ST-elevation in at least two contiguous leads, a new left bundle branch block or a true posterior myocardial infarction confirmed by ECG or echocardiography; Reperfusion is expected to be feasible within 12 h after onset of symptoms)
* Infarct related artery eligible for primary PCI (De novo lesion in a native coronary artery; Reference-vessel diameter ≥2.5 mm and ≤ 4 mm; Absence of severe calcification; Residual diameter stenosis of ≤30% (by visual assessment) after lesion preparation after lesion preparation; Absence of coronary dissection type ≥C.

Exclusion Criteria:

* Killip class\>II on admission
* Known contraindication for aspirin, clopidogrel, ticagrelor, heparin or GP IIb/IIIa inhibitor
* Previous myocardial infarction
* Previous PCI in the territory of the infarct-related artery (IRA)
* Previous CABG
* 3-vessel disease requiring revascularization
* Left-main disease
* Extremely angulated or severely calcified vessels
* History of ischemic stroke within the past 6 months or hemorrhagic stroke
* Planned CABG for a non-culprit vessel
* Participation in another investigational trial that has not completed its primary endpoint or could interfere with the endpoints of this study
Study the Safety and Efficacy of Probiotics Use in Premature Infants

Prophylactic enteral probiotics may enhance clinical markers and biomarkers of preterm infants' health, and may also play a role in reducing NEC and associated morbidity.


Eligibility Criteria:
Inclusion Criteria:

* born with weight\<1500 g
* hospitalized within 48 hours after birth

Exclusion Criteria:

* present with evidence or suspicion of congenital intestinal obstruction
* perforation
* gastroschisis
* large omphalocele
* congenital diaphragmatic hernia
* major congenital heart defects
Modulation Contrast Microscopy Imaging for Oocyte Quality Assessment

The present study aims to describe novel non-invasive parameters related to the competence of female reproductive cells (oocytes). In a fertility unit, human reproductive cells and embryos are subjected to different imaging technologies. Images can easily be obtained without disturbing the microenvironment during different standard procedures. Turning images into quantifiable data might provide a further understanding on oocyte behavior and performance in the laboratory.


Eligibility Criteria:
Inclusion Criteria:

* Intracytoplasmic sperm injection
* Embryo culture with subsequent fresh embryo transfer

Exclusion Criteria:

- Conventional IVF
Cyberbullying Among Sohag University Student

Cyberbullying can be defined as intentional aggression through electronic routes, such as text messages, e-mails, chat rooms, online games, and social websites. In comparison with traditional bullying, cyberbullying has many unique characteristics that boost its harmful effects, including the inability to avoid bullying, presence of larger and more potential audience, the continuity of bullying regardless of time or place, and the anonymity of perpetrator in many occasions .

In Egypt almost half of Beni-sueif university students (48.2%) reported experiencing cyberbullying victimization. Female students, students living in urban areas and those who spent more hours using the internet reported more exposure (p\<0.001). Harassment was the main type stated by females (79.8%) while flaming was excessively reported by males (51.8%). Students responded mostly by anger (63.1%), hatred (23.2%) and sorrow (22.6%) towards the worst victimization incidents.

In this study I want to study the situation of cyberbullying among Sohag University students .

, study patterns of cyberbullying among Sohag University students , determine of correlates of cyberbullying among Sohag University students such as family factors and study the implications of cyberbullying on victims .

Eligibility Criteria:
Inclusion Criteria:

* students of the selected faculties

Exclusion Criteria:

* students who will refuse to participate in this study.
Iron in Congestive Heart Failure

The hypothesis to be tested is whether treatment with intravenous iron (ferric carboxymaltose) will improve left-ventricular ejection fraction in patients with heart failure and iron deficiency as determined by cardiac magnetic resonance imaging.


Eligibility Criteria:
Inclusion Criteria:

* Congestive heart failure
* At least 18 years of age
* Iron deficiency
* Dyspnea class II or III according to New York Heart Association
* Left-ventricular ejection fraction ≤ 45%

Exclusion Criteria:

* Known sensitivity to any of the products to be administered during dosing
* Immediate need of transfusion
* Patients presenting with an active infection
* Thalassaemia
* Other forms of microcytic anemia not caused by iron deficiency
* History of acquired iron overload
* Need for revascularization, ST-segment elevation myocardial infarction or Non-ST-segment elevation myocardial infarction during the past 3 months (at time of randomization)
* Women who are pregnant or of childbearing age and not using medically acceptable effective contraception
Whole-slide Image and CT Radiomics Based Deep Learning System for Prognostication Prediction in Bladder Cancer

Bladder cancer (BLCA), with its diverse histopathological features and varying patient outcomes, poses significant challenges in diagnosis and prognosis. Postoperative survival stratification based on radiomics feature and whole slide image feature may be useful for treatment decisions to improve prognosis. In this research, we aim to develop a deep learning-based prognostic-stratification system for automatic prediction of overall and cancer-specific survival in patients with BLCA.

Bladder cancer can be difficult to diagnose and predict outcomes for, as the disease can vary greatly between patients. This research aims to develop a new system that uses artificial intelligence to analyze patient information, including images from surgery and scans. This system could then automatically predict a patient\&#39;s overall survival and how likely they are to survive specifically from bladder cancer. This information could be used by doctors to make better treatment decisions for each patient.

Eligibility Criteria:
Inclusion Criteria:

* patients with bladder cancer who had surgery like radical cystectomy or transurethral resection of bladder tumour (TURBT)
* contrast-CT scan less than two weeks before surgery
* complete CT image data and clinical data
* complete whole slide image data

Exclusion Criteria:

* patients with a postoperative diagnosis of non-urothelial carcinoma
* poor quality of CT images
* incomplete clinical and follow-up data
Calorie Balance Monitoring and Analysis of Body Composition and Hydration Status

The investigators are developing two new medical instruments: 1. the Intelligent Sensor Belt (ISB), and 2. the Body Composition and Hydration Status Analyzer (BC-HS-A). ISB serves the purpose of measuring calorie/ energy consumption of the human body during physical activity. The BC-HS-A measures the body composition, i.e. the fat and lean body mass and the hydration status i.e the amount of water inside and outside of the body cells.

The goal of this pilot study is to obtain data from the investigators prototype medical instruments: 1. ISB, and 2. BC-HS-A during physical exercise and compare those results with readings of other commercially available instruments or exercise equipments. The investigators would be testing for technical feasibility and, through comparison with existing measuring devices, the reliability of the investigators prototype.

Our goal is the development of a non-invasive, Portable Comprehensive Metabolic Monitoring System (PCMMS) for continuous measurement and monitoring of parameters of the human energy metabolism.

The current project focuses on the development of two hardware components of PCMMS: 1. the Intelligent Sensor Belt (ISB), and 2. the Body Composition (BC) \& Hydration Status (HS) Analyzer (BC--HS-A).

ISB is designed to be worn around the chest or waist and measures the energy expenditure of physical activity (PAE) via sensors for heart rate, tri-axial acceleration, and temperature.

BC-HS-A utilizes multi-frequency bio-impedance measurements through electrodes attached to one hand and opposite foot. This instrument is not used continuously but intermittently when momentary values of BC and HS are desired.

This pilot study is designed to obtain data from our instruments during a limited exercise session to gage its function and to determine its feasibility for the intended use. The pilot study will be performed on healthy volunteers who would wear ISB during a graded cardiac stress testing on various exercise machines such as the stationary bicycle, treadmill, stair case, and rowing machine. PAE measured by ISB will be compared with the estimated results of the particular exercise equipment. The BC measuring function of our BC-HS-A will be compared with a commercially available bioimpedance analyzer. Changes of hydration status during exercise measured by our BC-HS-A will be compared against precision measurements of body weight before and after exercise estimating total water loss of the body. All results will be reported in a peer-reviewed journal.

Eligibility Criteria:
Inclusion Criteria:

* interested participants who have maintained the same weight for several months and are healthy, are not pregnant and not wanting to become pregnant during the study period, do not take any drugs, and exercise regularly to maintain their weight will be invited.

Exclusion Criteria:

* patients taking medication for bodily illness/disease, women who are pregnant or wanting to become pregnant during the study period, and those who have not followed a regular exercise regimen will not be included in the trial
Heart Rate Variability in Children and Adolescents With Cystic Fibrosis

This study aims to assess the effects of a resistance exercise training program on heart rate variability in a group of children and adolescents with cystic fibrosis. The study design is a randomized controlled trial.

A randomized controlled study will be carried out in children diagnosed with cystic fibrosis aged 6 to 18 years. Individuals will be divided into two groups: control group (CON) and strength training (ST). Heart rate variability will be analyzed using KUBIOS and measured using a Suunto watch, with subjects in lying position without movements or speaking for 5 minutes. Patients in the ST group will complete an individualized guided strength program for 8 weeks (3 sessions of 60 min/week). Training prescription will be individualized and based on the 5 repetition maximum test (60-80%). Upper and lower limbs exercises will be used, including seated bench press, seated lateral row and leg press. Outcome measures will be performed at baseline and after 8 weeks.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of Cystic Fibrosis
* Age between 6 and 18 years old
* Mild to moderate lung function levels
* Signature of the informed consent form by legal guardian and patient.

Exclusion Criteria:

* Active smoking
* Exacerbation in the last 3 months
* Presence of gastrostomy
* Use of beta-blocker drugs
* Diagnosed heart disease
* Alterations in the locomotor system
Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients

Primary:

* Overall Survival (OS)

Secondary:

* Time to Tumor Progression (TTP)
* Response Rate (RR)
* Improvement of Quality of Life (QoL)
* Safety
* Secondary resection rate


Eligibility Criteria:
Inclusion Criteria:

* Histologically, cytologically or clinically diagnosed (in patient with cirrhosis, Alpha-Fetoprotein(AFP)≥400μg/L and morphological evidence \[contrast Computed Tomography(CT)/Magnetic Resonance Imaging(MRI)\] of hypervascular liver tumor, elevated AFP level due to other reasons \[germ cell carcinoma, progressive chronic hepatitis, pregnancy, etc\] can be excluded) unresectable hepatocellular carcinoma, ineligible or if the patient does not consent to receive local invasive treatment (chemo-embolism, ablation, etc.).
* At least one measurable lesion (on CT: ≥2cm, on spiral CT or MRI ≥1cm)
* Have not received previous palliative systemic chemotherapy for metastatic disease. If the patient received previous systemic chemotherapy as adjuvant treatment, he must have been completed at least 12 months previously.
* Patients progress after previous local treatment and at the time of randomization is at least 4 weeks after the last interventional therapy (Hepatic Artery Infusion, Trans-Artery Embolization or Trans-Artery Chemo-Embolization) or at least 8 weeks after the last radiotherapy/ablation/ Percutaneous Ethanol Injection to the target lesion.
* Karnofsky Performance Score≥70, Barcelona of Cancer Liver Category stage B/C
* Patients must have adequate organ and marrow function:

  * Neutrophilus≥1.5X10\^9/L
  * Platelets≥75X10\^9/L
  * Asparagine AminoTransferase,Alanine AminoTransferase\<2.5 Upper Normal Limit(UNL)
  * Total Bilirubin\<1.5 UNL
  * International Normalized Ratio\<1.5
  * Child stage A or B
  * Normal base line Left Ventricular Ejection Fraction (LVEF result must be above or equal to the lower limit of normal for the institution)

Exclusion Criteria:

* Documented allergy to platinum compound or to other study drugs.
* Any previous oxaliplatin or doxorubicin treatment, except adjuvant treatment more than 12 months before the randomization.
* Previous liver transplantation.
* Patients concomitantly receiving any other anti-cancer therapy, including interferon-α and herbal medicine which was approved by local authority to be used as "anti-cancer" medicine, except radiotherapy to non-target lesion (bone metastasis, etc)
* Patients who are receiving any other study treatments.
* Pregnant or lactating women or women of childbearing potential without proper contraceptive methods.
* History of other malignant diseases, except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix.
* Central nervous system metastasis
* Other serious illness or medical conditions

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
The Outcome of the Thrombopoietin Receptor Agonists in Pediatric Patient With Persistent or Chronic ITP Unresonsive to Steroids

Immune thrombocytopenic purpura (ITP) is an autoimmune disease characterized by a low platelet count, purpura, and hemorrhagic episodes caused by antiplatelet autoantibodies. The diagnosis is typically made by excluding the known causes of thrombocytopenia. IgG autoantibodies sensitize the circulating platelets. It leads to the accelerated removal of these cells by antigen-presenting cells (macrophages) of the spleen and sometimes the liver or other components of the monocyte-macrophage system. The bone marrow compensates for platelet destruction by increasing platelet production. ITP most often occurs in healthy children and young adults within a few weeks following a viral infection .

New treatment guidelines have supported a shift from corticosteroids and splenectomy to newer medical treatments that mitigate the thrombocytopenia and avoid splenectomy. The thrombopoietin receptor agonists (TPO-RA), romiplostim, eltrombopag have markedly altered the treatment of ITP.

The thrombopoietin receptor agonists (TPO-Ras) romiplostim and eltrombopag have shown high therapeutic activity In primary ITP.

Romiplostim, a thrombopoiesis-stimulating peptibody, represents a new therapeutic option in adult refractory chronic immune thrombocytopenia (ITP). This study aimed to assess the short-term efficacy and safety of romiplostim in children withChronic ITP.

The most commonly reported drug-related adverse effects include headache, nausea, and hepatobiliary laboratory abnormalities. Long-term safety data in children are limited, and studies in adults have not revealed a clinically significant increased incidence of thrombosis, marrow fibrosis, or cataract formation.

TPO-RA do not need to be continued forever; about a third of patients In the first year and about another third after two years have a remission. Whether TPO-RA affect the ITP pathophysiology and directly cause remission remains unclear. This review provides a personal overview of the diagnosis and treatment of ITP with a focus on the mechanism of action of TPO-RA, their place in the treatment algorithm, unique aspects of their clinical use, adverse effects.


Eligibility Criteria:
Inclusion Criteria:

pediatric patients with persistent or chronic Itp on thrombopoietin receptor agonists unresponsive to steroid.

Exclusion Criteria:

Any patient with other causes of thrombocytopenia. Any patient with chronic disease . Any patient with Acute ITP . Any newly diagnosed patient with ITP.
Effects of Compression Stockings in Asthma Symptoms At Night

Nocturnal worsening of asthma is common. It is characterized by overnight exacerbation of asthma symptoms such as shortness of breath, chest tightness, coughing, and wheezing, increased need of asthma medications and airway hyperresponsiveness, and decline in lung function (1). Nocturnal asthma has been attributed in part to circadian variations in lung function and airway inflammation. However, other factors including sleep, supine posture and lung volume may also contribute to nocturnal asthma. Current treatments often improve nighttime asthma symptoms. Nevertheless, nocturnal asthma is still common. Up to 2/3rd of asthma patients report nocturnal asthma symptoms, and many asthma related events occur at night, indicating poor asthma control. Results from an ongoing study suggest that in asthma while subjects were supine, fluid shifted out of the legs and accumulated in the thorax (rostral fluid shift) contributing to lower airway narrowing in asthma. A previou study has shown that wearing compression stockings during the day reduces fluid retention in the legs, reduces nocturnal rostral fluid shift out of the legs, and improves sleep apnea (2, 3). The aims of the proposed study is investigate whether off-the-shelf, below the knee compression stockings will attenuate nocturnal fluid shift and lower airway narrowing in asthma.


Eligibility Criteria:
Inclusion Criteria: non-smokers or former smokers (\<10 pack/year)

Exclusion Criteria: uncontrolled hypertension